A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This phase II trial evaluates whether a multi-antigen vaccine called STEMVAC improves disease-free survival after surgery in patients with triple-negative breast cancer (TNBC) and moderate or extensive residual cancer burden. TNBC has an aggressive clinical course and poorer disease-free survival compared to other subtypes. While patients who have no remaining tumor in the breast or lymph nodes after surgery have excellent long-term outcomes, patients with moderate or extensive residual cancer burden remain at high risk for early disease return and poorer prognosis. STEMVAC is designed to target proteins that tumor cells use when they become more aggressive and start to spread, and it is believed to work by boosting the immune system to recognize and destroy the invader tumor cells that are causing the disease. Giving STEMVAC after surgery may improve disease-free survival rates in TNBC patients with moderate or extensive residual cancer burden.
Sponsor: University of Washington
You may qualify if…
- ✓ At least 18 years of age
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2
- ✓ Triple-negative breast cancer as determined by the treating oncologist
- ✓ Completed standard of care neoadjuvant chemotherapy in the opinion of their treating oncologist
- ✓ Patients whose tumors progress on neoadjuvant therapy may be enrolled
- ✓ No clinical evidence of local or distant recurrence
- ✓ Plan to receive standard of care adjuvant directed therapy
- ✓ Completed standard of care locoregional treatment, including definitive breast and lymph node surgery followed by standard radiation therapy, if recommended
You may not qualify if…
- ✕ Toxicities related to prior exposure to immune checkpoint inhibitors for which immune checkpoint inhibitors cannot be safely continued as determined by study investigator
- ✕ Germline BRCA1 or BRCA2 mutations with adjuvant olaparib planned within the study period
- ✕ NOTE: If olaparib is not planned, then these patients are eligible
- ✕ Any known cardiac conditions:
- ✕ Symptomatic restrictive cardiomyopathy
- ✕ Dilated cardiomyopathy
- ✕ Unstable angina within 4 months prior to enrollment
- ✕ New York Heart Association functional class III-IV heart failure on active treatment
Where it's recruiting
Seattle
Source: ClinicalTrials.gov · NCT07721259 · last updated 2026-11-19